LPTX

Leap Therapeutics, Inc.

2.87 USD
+0.04 (+1.41%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Leap Therapeutics, Inc. stock is down -14.58% since 30 days ago. The next earnings date is Mar 22, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 7 March’s closed higher than February.

About Leap Therapeutics, Inc.

Leap Therapeutics, Inc. acquires and develops therapies for the treatment of cancer. DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers.